期刊文献+

沙利度胺联合用药抗肿瘤研究进展 被引量:6

Research progress of thalidomide in combination therapy for the treatment of tumor
下载PDF
导出
摘要 20世纪60年代沙利度胺因其具有致畸性而退出历史舞台,后来研究发现其致畸现象的背后是抗血管生成的作用。而抗血管生成作用这时已被学术界认为是对抗肿瘤生成的一个重要因素。后来,研究人员又发现了沙利度胺的其他抗肿瘤机制,这样沙利度胺便被作为一种极具潜力的抗肿瘤药物而被广泛研究。本文重点综述了沙利度胺的抗肿瘤作用机制以及它与其他药物联合用药用于治疗实体瘤的研究进展。 Following the reports of its teratogenicity, thalidomide was banned from the market in the 1960s. Later, researches discovered the teratogenicity was caused by inhibiting angiogenesis, and at that time the antiangiogenesis effect was considered an important factor in anti-tumour. Since then, many other anti-tumour mechanisms of thalidomide had been revealed and thalidomide was considered a kind of potential antitumor drug and was researched widely. This article focuses on the anti-tumour mechanisms of thalidomide and its use in combination therapy for the treatment of solid tumor.
作者 俞珊 季晖
出处 《中国临床药理学与治疗学》 CAS CSCD 2009年第2期230-236,共7页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 沙利度胺 抗肿瘤 联合用药 thalidomide anti-tumour combination therapy
  • 相关文献

参考文献7

二级参考文献26

  • 1张中林,刘志苏,孙权.反应停对人肝细胞癌生长侵袭的作用[J].中华实验外科杂志,2005,22(8):933-935. 被引量:8
  • 2Signhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Eng J Med, 1999,341:1565~1571.
  • 3Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist, 2001, 6: 81-91.
  • 4Tsavaris N, Ziras N, Kosmas C, et al. Two different schedules of irinotecan (CPT-11 ) in patients with advanced colorectal carcinoma relapsing after a 5-fluoreumeil and leucovorin combination: a randomized study. Cancer Chemother Pharmaeol, 2003, 52 : 514-519.
  • 5Tournigand C, Andre T, Achille E, et al. FORFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22:229-237.
  • 6Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet,2000, 356 : 566-567.
  • 7Go Vindarajan R,Heaton KM,Broadwater R,et al.Effect of thalidomkle on gastrointestinal toxic effects of irinotecan[J].Lancet,2000,356(9229):566-567.
  • 8de Gramont A,Figer A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18(16):2938-2947.
  • 9Miwa M,Ura M,Nishida M,et al.Design of novel oral fluoropyrimidine carbamate,capecitabine,which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer,1998,34(8):1274-1281.
  • 10Schuller J,Cassidy J,Dumont E,et al.Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J].Cancer Chemother Pharmacol,2000,45 (4):292-297.

共引文献62

同被引文献89

引证文献6

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部